Glioblastoma multiforme is a highly invasive and incurable primary brain tumor. The most frequent genetic alteration therein is amplification of the epidermal growth factor receptor (EGFR) gene, the target of current clinical trials. However, EGFR amplification is poorly adapted to glioblastoma cell lines. From the 30 cultures attempted herein, we were able to establish two glioblastoma tissue cultures with permanent cell lines. The remaining cultures showed limited life span and underwent senescence between passage numbers (PN) 8 to 15. Our newly established glioblastoma cell lines, designated 170-MG-BA and 538-MG-BA, both originated between PN 3 and 5 when areas of smaller, more rapidly proliferating cells appeared. Both cell lines showed similar rates of growth, moderate morphological differences, cytoskeletal heterogeneity and multiple chromosome re-arrangements. Analysis by molecular cytogenetics and comparative genomic hybridization (aCGH) revealed two copies of a stable marker chromosome in 170-MG-BA cells effecting focal amplification at 7q11 of the EGFR locus. Comparative RqPCR analysis confirmed that EGFR was uniquely highly expressed in 170-MG-BA cells. Combined targeted expression analysis and aCGH data excluded the recurrent EGFRvIII activating mutation. In contrast, EGFR expression in 538-MG-BA cells which lacked genomic EGFR amplification was not raised. Immunofluorescent staining showed high EGFR protein expression only in the 170-MG-BA cells. Cytogenetic, genomic and transcriptional analyses then confirmed high-level genomic amplification and transcriptional up-regulation of wild type EGFR in 170-MG-BA; the first conventional cell line model for investigating the biology and targeted therapy of this key alteration in glioblastoma. Both cell lines are freely available from the DSMZ cell repository.
address this phenomenon, notably by investigating cancer stem cells and identifying cancer initiating cells. High level genomic EGFR amplification (EGFR HIGH ) is the most frequent genomic alteration characterizing glioblastoma and affects about 40% cases, with a causal role in pathogenesis and treatment resistance [1] . EGFR is currently undergoing evaluation as a clinical target where trials have thrown up new challenges [2, 3] . Unfortunately, EGFR HIGH is seemingly unstable in conventional cell lines and can be only maintained short-term, such as the approximately five passages recently reported [4] . Although the DK-MG cell line bears high level (mutant) EGFR amplification, this is heterogeneous and affects a sub-population of cells, with others lacking amplification [5, 6] . Hitherto, one glioma cell line has been described with homogeneous EGFR amplification, SKMG-3, but it has only moderate amplification levels [7] .
Dearth of EGFR HIGH cell lines has necessitated undue reliance on ectopic expression models [8, 9] . While modified culture protocols have been developed to preserve wild type EGFR HIGH stability, notably withdrawal of receptor ligand EGF [9] , no conventional glioblastoma cell lines exist which preserve this key alteration to serve as a convenient laboratory tool for developing targeted therapies [9] . While more recent neurosphere models preserve additional glioma features, conventional cell lines are better suited for use in standardized drug response assays because these facilitate quantitative comparisons. EGFR HIGH is frequently (40-50%)
accompanied by expression of different variants/mutants, most often EGFRvIII [1, 10] -a deletion variant lacking exons 2-to-7 encoding the extracellular domain, an alteration which prevents EGF binding. EGFRvIII thus confers ligand-independent signaling by allowing hetero-dimerization to wild-type EGFR, thereby activating pathways other than those controlled by wild-type EGFR [11, 12] .
Of three barriers which have impeded the successful application of cancer cell lines -namely, mycoplasma infection, cross-contamination and unavailability, the former two have been addressed by technical advances first implemented by public cell repositories. The last remains a chronic problem, however, leaving several key entities under/un-represented by in vitro models [13] . Reasons for this dearth are the respective reluctance of some originators to make rare in vitro models freely available and of certain tumors to undergo establishment in vitro. Moreover, while several widely used glioma cell lines are available, retrospective authentication has revealed that too many of these bear questionable or false identities [14, 15, 16] . Thus, the unavailability of reliable glioma models covering the disease spectrum illustrates a chronic and widespread problem [17] . 
Growth kinetics
Proliferation rates were measured in 170-MG-BA and 538-MG-BA cell lines at PN 45-50.
Accordingly, growth curves were constructed from counts of the harvested cells. For counting we used the cells from five dishes in DIV 1 to 7. Chamber cell counting was accomplished by enumerating 20 marked microscopic fields.
Cytogenetic analysis
Cell lines were harvested and analyzed conventionally and by Spectral Karyotyping (SKY) [18] . Bacterial artificial chromosome (BAC) clone RP5-109e12 which carries EGFR Haemek, Israel) and FISH as previously described [19] .
Array comparative genomic hybridization (aCGH)
aCGH was performed as previously described [20] . CytoScan High Density Arrays which comprise parallel oligonucleotide and SNP probes (Affymetrix, High Wycombe, UK) were used to measure genomic copy number and losses of heterozygosity (LOH). DNA was prepared using the Qiagen Gentra Puregene Kit (Hilden, Germany). Labeling, hybridization and washing were performed with recommended kits and following manufacturers` protocols.
Quality control criteria were those defined by the manufacturer. Data was analyzed by Chromosome Analysis Suite software version 2.0.1.2 (Affymetrix).
Polymerase chain-reaction (PCR) analysis
Total RNA was extracted from cell line samples using TRIzol reagent (Invitrogen, Darmstadt, riming using Superscript II EGFRvIII mutation expression analysis using SensiFAST Probe HiROX-Kit (Bioline, Luckenwalde, Germany) and self-designed primer/probe-combinations specific for EGFRvIII and TBP as endogenous control (primer and probe sequences are given in Supplementary Table 1) . Analysis was performed by
StepOne Plus Realtime-PCR System with StepOne Software v2.1 (Applied Biosystems). Figure 2D ).
Results

Morphology of glioblastoma cell lines
Immunofluorescence
The results of indirect immunofluorescence staining for GFAP, vimentin (Vim), cytokeratins (CK), nestin (Nes) and nerofilaments (NF) are summarized in Table 1 and inter-heterogeneity of glioblastoma cell lines. The combination of these and our previous studies [25, 27] variant cannot be excluded [31] .
DNA STR profiles were both unique when compared with the global database available for interactive scrutiny at the DSMZ and ATCC, JCRB, and RIKEN repositories. Recent retrospective studies have cast doubt on the identity and stability of several classic glioma cell lines [14, 15, 16] , while others, such as SKMG-3, are subject to restricted distribution. The lack of a suitable and practical in vitro model has hampered investigation into the biology of EGFR HIGH which is the most frequent genomic alteration in malignant glioma and a major contributor to treatment resistance [1] . EGFR amplification is apparently unstable in conventional cell lines, with only the SKMG-3 glioma cell line described and only at moderate amplification levels [7] . This has hampered key investigations, such as identifying pathways disturbed by EGFR HIGH and how to mitigate them. Hence, provision of the newly 
